11 November 2014

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology announces that, since the last update in April 2014, there have been no changes to the numbers of shares block listed in respect of the Company's two option plans.

The table below provides further detail.

Name of company: Futura Medical plc
Name of scheme: Unapproved Share Option Scheme ("USOS")

EMI Share Option Scheme ("EMI")
Period of return: From: 28 April 2014
To: 10 November 2014
Number and class of securities not issued under the scheme(s) USOS: 1,786,435 ordinary shares of 0.2p
EMI: 1,828,306 ordinary shares of 0.2p
Total: 3,614,741
Number of securities issued under the scheme(s) during the period USOS: Nil
EMI: Nil
Balance under the scheme(s) of securities not yet issued at the end of the period USOS: 1,786,435
EMI: 1,828,306
Total: 3,614,741
Number and class of securities originally admitted and the date of admission USOS: 814,424 on 25 May 2011 and 1,193,959 on 8 October 2013
Total: 2,008,383 Total
EMI: 1,520,576 on 25 May 2011 and 1,476,041 on 8 October 2013
Total: 2,996,617 Total
Total: 5,005,000
Name of contact: Derek Martin, Chief Financial Officer
Telephone number of contact: +44 (0) 1483 685 670


For further information please contact:

Futura Medical plc
James Barder, Chief Executive
+44 (0) 1483 685 670

Nominated Adviser:
N+1 Singer
Aubrey Powell / Liz Yong / Thomas Smale
Tel: +44 (0) 20 7496 3000

For media enquiries please contact:

Buchanan Communications Limited
Mark Court / Sophie Cowles /
Stephanie Watson
Tel: +44 (0) 20 7466 5000


Notes to Editors:

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.